CompanyGraph
At a glance
- Depends onUpstream position: supplies 6 industries, depends on 3
- ScaleRevenue is $36,000, lower than 95% of all stocks globally
- PositionOperating margin is -267247.2%, lower than 95% of its Biotechnology peers (median -34.2%)
- Interpretations2 currently firing — 2
Sign in to view price data.
Sign inThe reported statements, read against the company's own industry.
Financials view
Market Capitalization
554.25MUSDvs all stocks (USD)
Revenue (TTM)
36.00KUSDvs all stocks (USD)
Profit Margin
0.00%vs Biotechnology peers
Beta
0.2410xvs all stocks
52-Week Change
-28.31%vs all stocks
Market Capitalization
554.25MUSDvs all stocks (USD)
Enterprise Value
283.84MUSDvs all stocks (USD)
Forward P/E
-3.47xvs Biotechnology peers
Price to Book (MRQ)
1.37xvs Biotechnology peers
Enterprise to Revenue
7.88Kxvs Biotechnology peers
Enterprise to EBITDA
-2.95xvs Biotechnology peers
Profit Margin
0.00%vs Biotechnology peers
Return on Assets (TTM)
-24.40%vs Biotechnology peers
Return on Equity (TTM)
-42.75%vs Biotechnology peers
Revenue (TTM)
36.00KUSDvs all stocks (USD)
Revenue per Share (TTM)
0.0005USDUpdated Jul 17, 2026Quarterly Revenue Growth
-100.00%vs Biotechnology peers
Gross Profit (TTM)
-66.05MUSDvs all stocks (USD)
EBITDA (TTM)
-96.10MUSDvs all stocks (USD)
Net Income (TTM)
-91.08MUSDvs all stocks (USD)
Quarterly Earnings Growth (YoY)
-100.00%vs Biotechnology peers
Operating Cash Flow (TTM)
-71.64MUSDvs all stocks (USD)
Levered Free Cash Flow (TTM)
-42.50MUSDvs all stocks (USD)
Payout Ratio
0.00%vs Biotechnology peers
Revenue
41.00KUSDFY2025 · Dec 31, 2025Operating Income
-94.49MUSDvs all stocks (USD)
Pre-tax Income
-88.77MUSDFY2025 · Dec 31, 2025Income Tax Expense
-681.00KUSDFY2025 · Dec 31, 2025Net Income
-88.09MUSDFY2025 · Dec 31, 2025EBIT
-87.14MUSDFY2025 · Dec 31, 2025EBITDA (Income Statement)
-87.03MUSDFY2025 · Dec 31, 2025Research & Development
66.43MUSDFY2025 · Dec 31, 2025Selling, General & Administrative
28.10MUSDFY2025 · Dec 31, 2025Non-operating Interest Income
7.54MUSDFY2025 · Dec 31, 2025Non-operating Interest Expense
1.64MUSDFY2025 · Dec 31, 2025EPS (Basic)
-1.00USDFY2025 · Dec 31, 2025EPS (Diluted)
-1.00USDFY2025 · Dec 31, 2025Basic Shares Outstanding
88.10MSharesFY2025 · Dec 31, 2025Diluted Shares Outstanding
88.10MSharesFY2025 · Dec 31, 2025Net Income from Continuing Operations
-88.09MUSDFY2025 · Dec 31, 2025Operating Cash Flow
-67.66MUSDFY2025 · Dec 31, 2025Free Cash Flow
-67.67MUSDFY2025 · Dec 31, 2025Cash & Cash Equivalents (End of Period)
43.80MUSDFY2025 · Dec 31, 2025Interest Paid
975.00KUSDFY2025 · Dec 31, 2025Starting Profit (CF Statement)
-88.09MUSDFY2025 · Dec 31, 2025Depreciation & Amortization
112.00KUSDFY2025 · Dec 31, 2025Deferred Taxes (CF)
-681.00KUSDFY2025 · Dec 31, 2025Stock-based Compensation
16.08MUSDFY2025 · Dec 31, 2025Other Non-cash Items
363.00KUSDFY2025 · Dec 31, 2025Change in Accounts Receivable (CF)
2.06MUSDFY2025 · Dec 31, 2025Change in Accounts Payable (CF)
2.51MUSDFY2025 · Dec 31, 2025Capital Expenditures
-11.00KUSDFY2025 · Dec 31, 2025Purchase of Investments
-285.45MUSDFY2025 · Dec 31, 2025Sale of Investments
152.99MUSDFY2025 · Dec 31, 2025Net Investing Cash Flow
-132.47MUSDFY2025 · Dec 31, 2025Long-term Debt Issuance
35.00MUSDFY2025 · Dec 31, 2025Other Financing Charges
-2.22MUSDFY2025 · Dec 31, 2025Net Financing Cash Flow
206.51MUSDFY2025 · Dec 31, 2025Shares Outstanding
130.22MSharesUpdated Jul 17, 2026Shares Short
47.63MSharesUpdated Jul 17, 2026Short Ratio
10.92daysvs all stocks
Short % of Shares Outstanding
24.52%vs all stocks
% Held by Insiders
0.41%vs all stocks
% Held by Institutions
58.07%vs all stocks
Total Cash (MRQ)
331.54MUSDvs all stocks (USD)
Total Cash per Share (MRQ)
1.71USDUpdated Jul 17, 2026Total Debt (MRQ)
35.85MUSDvs all stocks (USD)
Total Debt to Equity (MRQ)
0.1262xvs Biotechnology peers
Current Ratio (MRQ)
29.56xvs Biotechnology peers
Book Value per Share (MRQ)
2.18USDUpdated Jul 17, 2026Total Assets
279.93MUSDvs all stocks (USD)
Total Current Assets
278.19MUSDFY2025 · Dec 31, 2025Total Liabilities
55.04MUSDFY2025 · Dec 31, 2025Total Non-current Assets
1.74MUSDFY2025 · Dec 31, 2025Total Non-current Liabilities
40.04MUSDFY2025 · Dec 31, 2025Total Current Liabilities
15.00MUSDFY2025 · Dec 31, 2025Cash & Cash Equivalents
43.76MUSDFY2025 · Dec 31, 2025Other Short-term Investments
229.70MUSDFY2025 · Dec 31, 2025Accounts Receivable
1.22MUSDFY2025 · Dec 31, 2025Accounts Payable
2.72MUSDFY2025 · Dec 31, 2025Short-term Debt
256.00KUSDFY2025 · Dec 31, 2025Long-term Debt
35.43MUSDFY2025 · Dec 31, 2025Other Non-current Liabilities
4.45MUSDFY2025 · Dec 31, 2025Common Stock (Book)
11.00KUSDFY2025 · Dec 31, 2025Retained Earnings
-649.48MUSDFY2025 · Dec 31, 2025Total Shareholders' Equity
224.89MUSDvs all stocks (USD)
52-Week Low
2.56USDUpdated Jul 17, 202652-Week High
6.44USDUpdated Jul 17, 202652-Week Change
-28.31%vs all stocks
Beta
0.2410xvs all stocks
50-Day MA
2.92USDUpdated Jul 17, 2026200-Day MA
3.83USDUpdated Jul 17, 2026Avg 10-Day Volume
3.90MSharesUpdated Jul 17, 2026Avg 30-Day Volume
4.28MSharesUpdated Jul 17, 2026Diluted EPS (TTM)
-0.9400USDUpdated Jul 17, 2026Other Income / Expense
-190.00KUSDFY2025 · Dec 31, 20252 interpretations currently present — each is a set of fired observations whose alignment reads as one structural pattern. Click an observation to see the numbers behind it.
Screen for these patternsIs this company financially stable?
Low-Leverage Liquidity Configuration
Cash on hand covers most or all of its debt, and its equity share of assets is high for its industry.
Reads
Is this company growing?
Diagnostic
High R&D Share With Multi-Year Share-Count Growth and Elevated SBC
Heavy R&D and stock pay, with the share count growing across six years.
Reads
An interpretation is present only while every observation it reads stays fired (score ≥ 70). It describes what the aligned readings show — never a verdict, never a prediction.
Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Peer Positioning
Operating margin is -267247.2%, lower than 95% of its Biotechnology peers (median -34.2%)Significant
Operating margin: -2,672.472Industry median: -0.34Industry P5: -43.55Peers compared: 261
Current ratio is 29.56×, higher than 95% of its Biotechnology peers (median 5.64×)Significant
Current ratio: 29.56Industry median: 5.64Industry P95: 23.02Peers compared: 261
Financial Health
Low earnings qualitySignificant
Earnings Quality Score: -0.68
Altman Z-Score 2.9: safe zoneNotable
Altman Z-Score: 2.90
Supply Chain
Upstream position: supplies 6 industries, depends on 3Notable
Outgoing: 6.00Incoming: 3.00
Scale
Revenue is $36,000, lower than 95% of all stocks globallySignificant
Revenue (USD): 36,000Global P5: 30,274,777.221
Companies that share the same coordination system — how they create, deliver, or capture value.
Orchid Pharma Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Kingchem Liaoning Life Science Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Nanjing Well Pharmaceutical Group Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Assure Tech Hangzhou Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Boryung Co. Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Relmada Therapeutics Inc.
Tier 1ProductionApproval-Gated PipelineRule
Morepen Laboratories Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
CHA Biotech Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleInterface
Shaanxi Kanghui Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
NeuroPace Inc.
Tier 1ProductionApproval-Gated PipelineRule
Companies that share active interpretations — structural patterns currently present in both stocks.
Rigetti Computing Inc
2 interpretationsHigh R&D Share With Multi-Year Share-Count Growth and Elevated SBCLow-Leverage Liquidity Configuration
Archer Aviation Inc.
2 interpretationsHigh R&D Share With Multi-Year Share-Count Growth and Elevated SBCLow-Leverage Liquidity Configuration
IonQ, Inc.
2 interpretationsHigh R&D Share With Multi-Year Share-Count Growth and Elevated SBCLow-Leverage Liquidity Configuration